9-7-2021 SmallCapVoice Interview with (OTC: USAQ)

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Troy Grogan, CEO of USA Equities Corp. (OTCQB:USAQ), to discuss the Company’s recent news and the drivers behind the strong Q2 2021 financial results.

“During the second quarter we acquired the method patent, trademark and website to AllergiEnd®, including rights to FDA-cleared diagnostic equipment and treatments that allow primary care providers to diagnose and treat many common chronic allergies in their offices. The asset purchase provides USAQ the opportunity to more fully integrate and leverage these products across our marketing platform, customer relationships and cost structure. AllergiEnd®’s addressable market is large and growing with the number of people in the U.S. affected by allergic disorders currently estimated to be over 60 million, and is expected to grow in the double digits while the number of full-time allergists and immunologists is expected to decline. The AllergiEnd line of products and procedures are fully reimbursable under existing government and private insurance programs.

Second Quarter 2021 Financial Results

*USAQ began selling AllergiEnd® Allergy Diagnostics and Allergen Immunotherapy treatments in the fourth quarter of 2020.

Total revenue for the three months ended June 30, 2021 was $455,622, an increase over revenue of $304,336 reported in the first quarter of 2021. The increase reflects growth in both Allergy Diagnostic Kits and Immunotherapy Treatment sales.

Second-quarter 2021 sales of Allergy Diagnostic Kits of $272,864 compared to $187,040 in the first quarter; second-quarter 2021 sales of Immunotherapy Treatments were $169,579 compared to sales of $107,853 in the prior quarter.

The Company generated gross profit of $207,120, or a gross margin of approximately 45.5% in second quarter 2021 compared to gross profit of $133,579 or a gross margin of 43.9% in first quarter 2021. The increase was primarily attributable to the larger base of sales as well as customer and product mix.

Sales and marketing expenses of $161,619 in second quarter 2021 compared to $111,688 in first quarter 2021, as the Company hired additional sales personnel and further expanded the launch of products.

General and administrative expenses of $134,694 in first quarter 2021 compared to $70,127 in first quarter 2021.

USA Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow general practice physicians and other medical practitioners to increase revenues by cost effectively diagnosing and treating chronic diseases that heretofore would only have been referred to a specialist for treatment. The Company’s products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary products and software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular disease populations.

For additional information, visit the Company’s website at www.USAQCorp.com